Drug Discovery@nature.com 2 March 2012

Advertisement THE BEST CHOICE FOR HUMANIZATION EXPERIMENTS: The CIEA NOG mouse® • The most immunodeficient mouse. • The best for difficult xenografts. • The easiest purchase process.  No MTA or license fees. • Simply the best. The CIEA NOG mouse®. Validated in 100+ publications on immunology, oncology, infectious disease, and more. Contact Taconic to learn more. TABLE OF CONTENTS 2 March 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Scientific Reports published the most downloaded paper on nature.com in December. Downloaded over 100,000 times and counting... Make your paper seen. Make your paper open. Submit to Scientific Reports.   News Top Childhood drug studies show room for improvement doi:10.1038/nature.2012.10132 Report finds recent laws have enhanced US child medicine, but some drugs are still used without rigorous testing. Full Text Reverse vaccinology on the cusp doi:10.1038/nrd3679 An upcoming decision for Novartis's Bexsero - the first vaccine against meningococcus B - could substantiate reverse vaccinology. Full Text Protein–protein interaction inhibitors get into the groove doi:10.1038/nrd3680 Drug developers are getting closer to tapping an unmined gold reserve of protein-protein interaction targets. Full Text Market watch: Industry perspectives on personalized medicine doi:10.1038/nrd3677 To better understand the current role of personalized medicine and pharmacogenomics in drug development, interviews and a follow-up survey of a group of companies about the current role of personalized medicine and pharmacogenomics in their company were conducted. Full Text Analysis Top Cystic fibrosis two-step doi:10.1038/scibx.2012.192 Two teams have independently shown that restoring normal function to mutant CFTR requires correcting two distinct folding steps. The findings could provide a road map to guide the rational development of more effective therapies to treat cystic fibrosis. Full Text Fresh from the Pipeline: Tafamidis doi:10.1038/nrd3675 In November 2011, the first-in-class drug tafamidis (Vyndaqel; Pfizer), which inhibits protein misfolding, was approved in Europe for the treatment of familial amyloid polyneuropathy. Full Text From the analyst's couch: Maximizing the value of diagnostics in Alzheimer's disease drug development doi:10.1038/nrd3535 This article examines strategic issues faced by pharmaceutical companies relating to the development of biomarkers and diagnostics for Alzheimer's disease. Full Text Research Highlights Top Neurodegenerative disease: Harnessing virus-mediated mitochondrial protection to combat neurodegeneration doi:10.1038/nrd3688 A novel therapeutic strategy could have important implications for the treatment of Parkinson's disease and other neurodegenerative diseases involving impaired mitochondrial function. Full Text Anticancer drugs: Targeting menin doi:10.1038/nrd3689 Inhibitors that target the interaction between menin and MLL could be useful for the treatment of acute lymphocytic leukaemia. Full Text Angiogenesis: Scheduled delivery doi:10.1038/nrc3232 Angiogenesis inhibitors may not provide clinical benefit by normalizing blood vessels and thereby increasing the delivery of chemotherapy, as has been hypothesized. Full Text Research & Reviews Top Diagnosing the decline in pharmaceutical R&D efficiency doi:10.1038/nrd3681 The authors of this Perspectives article discuss four factors that they consider to contribute significantly to the decline in pharmaceutical R&D efficiency. Full Text The insulin and insulin-like growth factor receptor family in neoplasia: an update doi:10.1038/nrc3215 Possible reasons for the disappointing outcomes of Phase III clinical trials for therapies targeting the insulin and insulin-like growth factor I receptor family, potential next steps and relevance to other areas of drug development in oncology are the subject of this Review. Full Text Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors doi:10.1038/nbt.2121 PARP inhibitors have recently entered Phase III clinical trials as cancer therapeutics, but the specificity of many of these compounds is unknown. Wahlberg et al. used biochemical approaches to show that most PARP inhibitors target multiple PARP family members. Full Text Activin-like kinase 3 is important for kidney regeneration and reversal of fibrosis doi:10.1038/nm.2629 Raghu Kalluri and colleagues have identified an orally available, small-peptide agonist of activin-like kinase 3, the key co-receptor for BMP7 in the kidney, that reduces established fibrosis in animal models of kidney injury. Full Text Drug Discovery JOBS of the week Research Fellow in Targeted Therapies for Cancer The University of Michigan, Department of Pathology Medical Safety Advisor Drug Safety (m / w) Hays AG Post-Doc in Drug Discovery and GPCR Pharmacology The Scripps Research Institute - Florida, Bohn Lab Associate Manager Drug Safety Gilead Sciences Internship in evaluation of the in-vivo racemization of drugs at least for 6 months 1500 Merck KGaA More Science jobs from Drug Discovery EVENT The Drug Development Process - from Discovery to Commercialization 14.-16.03.12 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.